지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2013.1
- 수록면
- 114 - 118 (5page)
이용수
초록· 키워드
오류제보하기
Objectives: To assess the clinical efficacy of once-yearly treatment with Zoledronic acid in patients with osteopenia.
Materials and Methods: From June 2009 to November 2011, patients diagnosed with osteopenia were applied to fracture risk assessment tool (FRAX). Among them, 40 patients who showed high possibility of osteoporotic fracture were selected and treated with intravenous zoledronic acid once-yearly. At the baseline and after one year of injection of zoledronate, we measured the changes in the bone mineral density (BMD) and bone turnover markersIn addition, we analyzed the side effects and thereby assessed the drug safety.
Results: Mean 10 year probability of fracture calculated by FRAX tool was 4.2±1.8% for hip fracture, and 17.7±4.3% for other major osteoporotic fracture. Mean T-score was -1.89±0.42 at baseline and -1.71±±0.54 at 1 year after treatment. But this differences did not reachstatistical significance (P>0.05). Mean C-telopeptide levels were 0.35±±0.32 ng/mL and 0.22±±0.16 ng/mL, , mean osteocalcin levels were 13.64±5.15 ng/mL and 11.7±6.02 ng/mL before and after treatment. These differences reached a statistical significance (P<0.001). During the treatment, there were no serious adverse effects.
Conclusions: Once-yearly treatment with Zoledronic acid was effective in reducing bone resorption in patients with osteopenia. In addition, the BMD levels were slightly increased. But this was not statistically significant. Further long-term follow-up studies are warranted to assess the efficacy of a once-yearly treatment with Zoledronic acid in patients with osteopenia.
목차
등록된 정보가 없습니다.
참고문헌 (20)
참고문헌 신청
/ / National osteoporosis Foundation-Clinicians guide to prevention and treatment of osteoporosis
Anonymous / 1993 / Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis / Am J Med 94 : 64 ~ 50
Black DM / 2006 / Effect of once-yearly infusion of zoledronic acid 5 mg on spine and hip fracture reduction in postmenopausal women with osteoporosis: the HORIZON pivotal f
Black DM / 2007 / Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis / N Engl J Med 356 : 1809 ~ 1822
Chesnut CH 3rd / 1997 / Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bo
Anonymous / 1993 / Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis / Am J Med 94 : 64 ~ 50
Black DM / 2006 / Effect of once-yearly infusion of zoledronic acid 5 mg on spine and hip fracture reduction in postmenopausal women with osteoporosis: the HORIZON pivotal f
Black DM / 2007 / Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis / N Engl J Med 356 : 1809 ~ 1822
Chesnut CH 3rd / 1997 / Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bo
이 논문의 저자 정보
최근 본 자료
댓글(0)
0